Jennison Associates
XLRN

Jennison Associates’s Acceleron Pharma XLRN Stock Holding History

Jennison Associates’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-30,041
Closed -$767K – 821
2016
Q4 		$767K Buy
+30,041
New +$952K ﹤0.01% 635
2014
Q4 		– Sell
-49,863
Closed -$1.51M – 769
2014
Q3 		$1.51M Buy
49,863
+75
+0.2% +$2.11K ﹤0.01% 610
2014
Q2 		$1.69M Sell
49,788
-5,765
-10% -$193K ﹤0.01% 584
2014
Q1 		$1.92M Buy
55,553
+187
+0.3% +$8.44K ﹤0.01% 593
2013
Q4 		$2.19M Buy
+55,366
New +$1.34M ﹤0.01% 558

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Jennison Associates's XLRN Position: Q1 2017 in Review

Jennison Associates sold out of Acceleron Pharma (XLRN) in Q1 2017, closing a stake of 30,041 shares — an estimated $767K sold.

Jennison Associates first reported a position in XLRN in Q4 2013 and held it in 5 quarters. The position peaked at $2.19M in Q4 2013. 136 funds tracked by Wall St. Rank hold XLRN as of Q1 2017.

  • Jennison Associates reported no remaining Acceleron Pharma position as of Q1 2017 after selling out during the quarter.
  • Jennison Associates sold 30,041 Acceleron Pharma shares in Q1 2017, an estimated $767K.
  • Jennison Associates first reported a position in Acceleron Pharma in Q4 2013 and held it in 5 quarters.
  • Jennison Associates's Acceleron Pharma position peaked at $2.19M in Q4 2013.
  • 136 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2017.

Based on Jennison Associates's 13F filing for Q1 2017, filed 28 Apr 2017.